77%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
77%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
77%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
77%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Ardelyx Inc
Closed
SectorHealthcare
3.87 14.5
Overview
Share price change
24h
Min
3.38
Max
4.03
Income | -46M -41M |
|---|---|
Sales | -42M 74M |
EPS | -0.17 |
Profit margin | -55.514 |
Employees | 395 |
EBITDA | -47M -36M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +221.65% upside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | -496M 845M |
|---|---|
Previous open | -10.63 |
Previous close | 3.87 |
News Sentiment
By Acuity
75%
25%
356 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Ardelyx Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ardelyx Inc Forecast
Price Target
By TipRanks
221.65% upside
12 Months Forecast
Average 10.55 USD 221.65%
High 15 USD
Low 5.5 USD
Based on 10 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.
Sentiment
By Acuity
356 / 382 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
